SkinBioTherapeutics - Update on Board Investigation
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")
Update on Board Investigation
· Very recent new information has led the Board to seek the reversal of all accrued royalty income from the audited FY25 revenues
· Company supported by robust cash balance of
· Process underway to appoint an interim CEO in near term and thereafter a new, permanent CEO
Over recent days, the Board has been urgently conducting an investigation of the business ("the Board Investigation"), following initial concerns over matters of conduct by the former CEO, who was first suspended and who has since resigned [Release link]. In addition to the initial concerns around his conduct, in light of the newly available information, the Board has reason to believe that the former CEO has misrepresented material information to the Board and senior management, the Company's auditors and advisors. The former CEO was informed of these allegations on Sunday
Information received late on Friday
Whilst the Board believes this is an isolated incident, nevertheless, it has instigated a broader investigation to review all of the Group's businesses with respect to financial reporting and operations.
The findings of the Board Investigation to date, together with the information received late on Friday
· Contracts held with key partners and customers remain sound;
· Strong future potential of the SkinBiotix® technology and the Company's strategy to develop products in skin care and skin health;
· Accrued Royalty Income was included in the audited FY25 accounts due to a potential misrepresentation, therefore the Board has taken the decision to seek to reverse these sums from the Group FY25 accounts completely, subject to confirmation by the Company's auditors;
· Dermatonics and Bio-Tech Solutions are operating as reported at FY25 (audited revenues of
· Direct product sales of AxisBiotix™ are reported correctly in FY25; the partnership with Superdrug Stores plc ("Superdrug") is still at a very early stage;
· The Company has a robust cash position which was reported as
The Board believes that the estimated impact of the expected reversal of FY25 Accrued Royalty Income on the audited FY25 results will be as follows:
· FY25 revenue will become
· Adjusted EBITDA for FY25 will be restated to a loss of
· The expected adjustments will be agreed following a review by the Company's auditors
As a result of the Board's Investigation and the subsequent expected removal of the FY25 Accrued Royalty Income, the Board now anticipates that the results for the year ended
The Company's search to find an interim CEO and to find a new, permanent CEO for the longer term is progressing and further announcements will be made in due course.
* Market expectations for the year ending
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc |
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 020 7496 3000
|
|
Vigo Consulting |
+44 (0) 20 7390 0230 |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE